Last updated on August 2019

A Study to Test the Effectiveness and Safety of Fremanezumab on Patients With Fibromyalgia


Brief description of study

The primary objective of the study is to estimate the treatment effect of fremanezumab administered subcutaneously in reducing pain in adult patients with FM. A secondary objective is to evaluate the effect of fremanezumab on other efficacy measures, including pain, quality of life, sleep, fatigue, improvement in health, physical functioning, and mood. Another secondary objective is to evaluate the safety and tolerability of fremanezumab administered subcutaneously in adult patients with FM.

The total duration of patient participation in the study is planned to be 35 weeks, consisting of the screening period of up to 5 weeks, the double-blind treatment period of 16 weeks, and the 14-week follow-up period.

Clinical Study Identifier: NCT03965091

Find a site near you

Start Over

Teva Investigational Site 14169

Salt Lake City, UT United States
8.65miles
  Connect »